Under construction – not a live service
Sign in
Not yet taking people in TürkiyeNo phase

Comparing 27-inch and 55-inch screens used during endometrial cancer surgery

Compares two screen sizes used in keyhole surgery for women with endometrial cancer.

Key facts

Who runs it
Metehan Uzundal
Where
Istanbul, TürkiyeSee the site
Trial code
Registry title
27-Inch Versus 55-Inch Monitors in Women Undergoing Endometrial Cancer Surgery
Status
Not yet recruiting
People taking part
70 people, planned
Started
Oct 2026
Expected to end
Feb 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • 27-Inch Endoscopic Imaging Monitor
  • 55-Inch Endoscopic Imaging Monitor
Record updated
20 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 18 or older with endometrial cancer who are planned for keyhole (laparoscopic) surgery with sentinel lymph node removal. It compares a 27-inch and a 55-inch screen used during surgery.

Age
18 years or older
Sex
Women only
Disease stage
Endometrial cancer confirmed by tissue examination, with surgery planned. No distant spread (metastasis).
Earlier treatment
No history of abdominal surgery through a midline incision, no myomectomy, no tubo-ovarian abscess, and not three or more cesarean deliveries.
Biomarker or test result
Preoperative hemoglobin of 10 g/dL or higher.

Main reasons for not taking part

  • Distant spread of the cancer found before surgery
  • Body mass index of 40 kg/m² or higher
  • Uterus the size of a 12-week pregnancy or larger
  • Severe heart or lung disease that rules out keyhole surgery
  • Hemoglobin below 10 g/dL before surgery

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Female patients aged 18 years or older
  • Histologically diagnosed endometrial cancer with planned surgical treatment
  • Eligible for minimally invasive surgery
  • Planned total laparoscopic hysterectomy with bilateral salpingectomy or bilateral salpingo-oophorectomy and sentinel lymph node dissection
  • No severe systemic disease that would contraindicate laparoscopic surgery based on preoperative evaluation
  • Standard cervical four-quadrant indocyanine green injection planned for sentinel lymph node mapping
  • Bilateral sentinel lymph node mapping and bilateral sentinel lymph node dissection feasible during surgery
  • Preoperative hemoglobin level of 10 g/dL or higher
  • Able and willing to provide written informed consent

Who cannot take part

  • Need for an additional major surgical procedure outside the standardized surgical protocol
  • Not suitable for minimally invasive surgery, such as severe cardiopulmonary disease
  • Failure of bilateral sentinel lymph node mapping or inability to perform bilateral sentinel lymph node dissection
  • History of abdominal surgery through a midline incision
  • History of myomectomy
  • History of tubo-ovarian abscess
  • History of three or more cesarean deliveries
  • Preoperative hemoglobin level below 10 g/dL
  • Distant metastasis detected on preoperative imaging or clinical evaluation
  • Conversion from laparoscopy to laparotomy
  • Systematic pelvic and/or para-aortic lymph node dissection performed
  • Body mass index of 40 kg/m² or higher
  • Uterine size equivalent to 12 weeks of gestation or larger
  • Dense bowel or omental adhesions detected intraoperatively
  • Refusal to participate or inability to provide informed consent

Where in Türkiye

  • Başakşehir Çam and Sakura City HospitalIstanbul, TürkiyeContact: Metehan Uzundal, MDNo longer taking part

About the trial

What the trial wants to find out

This study will compare the use of 27-inch and 55-inch endoscopic imaging monitors during minimally invasive surgery for women with endometrial cancer. Participants will be randomly assigned to one of the two monitor groups. All participants will undergo the same standard surgical procedure; only the monitor size used during surgery will differ. The main question is whether monitor size affects total operative time. The study will also evaluate sentinel lymph node dissection time, blood count changes, complications, infections, hospital stay, and drain-related outcomes during the first 30 days after surgery.

The 2 groups in the trial

  • 27-Inch Monitor GroupTreatment being tested

    Participants randomized to this arm will undergo minimally invasive endometrial cancer surgery using a 27-inch 4K-2D endoscopic imaging monitor. The surgical procedure and perioperative care will be standardized.

    Treatment: 27-Inch Endoscopic Imaging Monitor

  • 55-Inch Monitor GroupExisting treatment, for comparison

    Participants randomized to this arm will undergo the same minimally invasive endometrial cancer surgery using a 55-inch 4K-2D endoscopic imaging monitor. The surgical procedure and perioperative care will be standardized.

    Treatment: 55-Inch Endoscopic Imaging Monitor

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Effect of 27-Inch and 55-Inch Endoscopic Imaging Monitors on Surgical and Postoperative Outcomes in Endometrial Cancer Surgery: A Randomized Controlled Trial
Plain-language title
Comparing 27-inch and 55-inch screens used during endometrial cancer surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
20 October 2026